The AI in Business Podcast Leveraging AI for Better Outcomes Across Drug Development - with Patricio La Rosa of Bayer
May 13, 2025
Patricio La Rosa, Head of End-to-End Decision Science at Bayer, brings over 20 years of experience in AI and data science. He discusses how AI optimizes drug development, improving trial planning and patient engagement. The conversation highlights the ethical implications of AI, emphasizing the importance of transparency and trust in clinical settings. Patricio also explores barriers to AI adoption and offers strategies for integrating AI into decision-making processes, drawing valuable lessons from agriculture and retail to enhance healthcare outcomes.
AI Snips
Chapters
Transcript
Episode notes
AI Humanizes Clinical Trials
- AI enhances drug development by predicting patient outcomes more accurately and personalizing patient engagement.
- It transforms clinical trials into more human-centric processes rather than just lab experiments treating individuals as objects.
Metagenomics Meets AI Biomarker Detection
- Metagenomics genetic sequencing helps detect bacteria biomarkers without growing cultures.
- AI helps estimate abundances and correct sampling effects to identify biomarkers for rare diseases faster.
Stable Biomarkers Are Key Challenge
- A critical challenge in clinical trials is proving biomarkers remain stable across various sites and machines.
- Without consistent biomarkers, effective drug development and approval are impossible.